Asahi Group Holdings would begin making minority investments in US start-ups from January 2023 through its Asahi Group Beverages & Innovation Fund which will open up new markets for low-alcohol and non-alcohol beverages.
The fund will support US start-ups that have "attractive brands" with significant future growth potential in the non-alcoholic beer-taste beverages, adult soft drink beverages, and low-alcohol categories.
It would also support start-ups with technology that leads to new sales and manufacturing methods, according to Atsushi Katsuki, president and CEO of Asahi Group Holdings.
Asahi will use its business platform to encourage sales growth for the goods and services offered by such enterprises both domestically and internationally.
By the end of 2025, the total investment is anticipated to be around $70 million. Employees recruited from the regional headquarters of Asahi Group will serve as the investment managers for Asahi Group Beverages & Innovation.


South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
The Beauty Beneath the Expressway: A Journey from Self to Service
Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 



